Correction: Cardiovascular Diabetology (2023) 22:62 https://doi.org/10.1186/s12933-023-01773-z
Following the publication of the original article [1], the authors identified errors in Fig. 2 introduced during the final production phase. Specifically, the sample size numbers in the rows for 'Look AHEAD,' 'ADOPT,' 'BARI2D,' 'RECORD,' 'TOSCA.IT,' and 'Total' were garbled. The results were not affected. The corrected Fig. 2 has been provided with this correction.
Efficacy of antihyperglycemic drugs on the risk of major adverse cardiovascular events (MACE). UKPDS 33, ACCORD, ADVANCE, VADT: trials comparing an intensive glycemic control strategy with standard care; Look AHEAD: a trial comparing intensive lifestyle intervention for weight loss with standard care; ORIGIN: a trial comparing insulin glargine with standard care; ACE: a trial comparing acarbose (α-glucosidase inhibitor [α-GI]) with placebo; PROactive, ADOPT, DREAM, BARI 2D, RECORD, AleCardio, IRIS, TOSCA.IT: trials comparing peroxisome proliferation-activated receptor (PPAR) agonists with placebo or active control drug; EXAMINE, SAVOR-TIMI 53, TECOS, OMNEON, CARMELINA: trials comparing dipeptidyl-peptidase-4 inhibitors (DPP-4i) with placebo; ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, PIONEER 6, AMPLITUDE-O, FREEDOM-CVO: trials comparing glucagon-like peptide-1 receptor agonists (GLP-1RA) with placebo; EMPAREG-OUTCOME, CANVAS-Program, DECLARE-TIMI 58, CREDENCE, VERTIS CV, SCORED: trials comparing sodium-glucose cotransporter-2 inhibitors (SGLT2i) with placebo
The original article has been updated.
Reference
Hasebe M, Yoshiji S, Keidai Y, Minamino H, Murakami T, Tanaka D, Fujita Y, Harada N, Hamasaki A, Inagaki N. Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. Cardiovasc Diabetol. 2023;22:62.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Hasebe, M., Yoshiji, S., Keidai, Y. et al. Correction: Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. Cardiovasc Diabetol 22, 95 (2023). https://doi.org/10.1186/s12933-023-01825-4
Published:
DOI: https://doi.org/10.1186/s12933-023-01825-4